Evaluation of the Therapeutic Potential of the Novel Isotype Specific HDAC Inhibitor 4SC-202 in Urothelial Carcinoma Cell Lines

Targeted Oncology

Volumn 11, Issue 6, 2016, Pages 783-798

  Pinkerneil, Maria ^a   Hoffmann, Michèle J ^a   Kohlhof, Hella ^b   Schulz, Wolfgang A ^a   Niegisch, Günter ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b 4SC AG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

4SC 202; ALPHA TUBULIN; CASPASE 3; CASPASE 7; HISTONE DEACETYLASE 1; HISTONE DEACETYLASE 2; HISTONE DEACETYLASE 3; HISTONE DEACETYLASE INHIBITOR; LACTATE DEHYDROGENASE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; UNCLASSIFIED DRUG; VORINOSTAT; IMMUNOGLOBULIN CLASS;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CARCINOMA CELL LINE; CELL DIFFERENTIATION; CELL GROWTH; CELL PROLIFERATION; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DNA DAMAGE; DRUG EFFICACY; DRUG RESPONSE; G2 PHASE CELL CYCLE CHECKPOINT; GROWTH INHIBITION; HISTONE ACETYLATION; HUMAN; HUMAN CELL; IC50; MITOSIS; PRIORITY JOURNAL; PROTEIN ACETYLATION; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; TRANSITIONAL CELL CARCINOMA; GENETICS; TUMOR CELL LINE; URINARY BLADDER NEOPLASMS;

CELL LINE, TUMOR; HISTONE DEACETYLASE INHIBITORS; HUMANS; IMMUNOGLOBULIN ISOTYPES; URINARY BLADDER NEOPLASMS;

EID: 84976618956     PISSN: 17762596     EISSN: 1776260X     Source Type: Journal    
DOI: 10.1007/s11523-016-0444-7     Document Type: Article

References (53)

1. De Santis M, Bellmunt J, Mead G, Kerst JM, Leahy M, Maroto P, et al. Randomized phase II/III trial assessing gemcitabine/carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: EORTC study 30986. J Clin Oncol. 2012;30(2):191–9.
2. Sternberg CN, de Mulder PH, Schornagel JH, Theodore C, Fossa SD, van Oosterom AT, et al. Randomized phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: European Organization for Research and Treatment of Cancer Protocol no. 30924. J Clin Oncol. 2001;19(10):2638–46.
3. von der Maase H, Sengelov L, Roberts JT, Ricci S, Dogliotti L, Oliver T, et al. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol. 2005;23(21):4602–8.
4. Reddy K. Phase III, study of sunitinib malate (SU11248) versus interferon-alpha as first-line treatment in patients with metastatic renal cell carcinoma. Clin Genitourin Cancer. 2006;5(1):23–5.
5. Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Staehler M, et al. Sorafenib for treatment of renal cell carcinoma: final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J Clin Oncol: Off J Am Soc Clin Oncol. 2009;27(20):3312–8. doi:10.1200/JCO.2008.19.5511.
6. Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S, et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet. 2008;372(9637):449–56. doi:10.1016/S0140-6736(08)61039-9.
7. Ghosh M, Brancato SJ, Agarwal PK, Apolo AB. Targeted therapies in urothelial carcinoma. Curr Opin Oncol. 2014;26(3):305–20. doi:10.1097/CCO.0000000000000064.
8. Niegisch G, Lorch A, Albers P. Chemotherapy for urothelial cancer of the bladder—update 2012. Aktuelle Urol. 2012;43(6):412–9. doi:10.1055/s-0032-1327699.
9. Knievel J, Schulz WA, Greife A, Hader C, Lubke T, Schmitz I, et al. Multiple mechanisms mediate resistance to sorafenib in urothelial cancer. Int J Mol Sci. 2014;15(11):20500–17.
10. de Ruijter AJ, van Gennip AH, Caron HN, Kemp S, van Kuilenburg AB. Histone deacetylases (HDACs): characterization of the classical HDAC family. Biochem J. 2003;370(Pt 3):737–49. doi:10.1042/BJ20021321.
11. Gregoretti IV, Lee YM, Goodson HV. Molecular evolution of the histone deacetylase family: functional implications of phylogenetic analysis. J Mol Biol. 2004;338(1):17–31. doi:10.1016/j.jmb.2004.02.006.
12. Witt O, Deubzer HE, Milde T, Oehme I. HDAC family: what are the cancer relevant targets? Cancer Lett. 2009;277(1):8–21. doi:10.1016/j.canlet.2008.08.016.
13. Weichert W, Roske A, Gekeler V, Beckers T, Ebert MP, Pross M, et al. Association of patterns of class I histone deacetylase expression with patient prognosis in gastric cancer: a retrospective analysis. Lancet Oncol. 2008;9(2):139–48. doi:10.1016/S1470-2045(08)70004-4.
14. Weichert W, Roske A, Gekeler V, Beckers T, Stephan C, Jung K, et al. Histone deacetylases 1, 2 and 3 are highly expressed in prostate cancer and HDAC2 expression is associated with shorter PSA relapse time after radical prostatectomy. Br J Cancer. 2008;98(3):604–10. doi:10.1038/sj.bjc.6604199.
15. Weichert W, Denkert C, Noske A, Darb-Esfahani S, Dietel M, Kalloger SE, et al. Expression of class I histone deacetylases indicates poor prognosis in endometrioid subtypes of ovarian and endometrial carcinomas. Neoplasia. 2008;10(9):1021–7.
16. Yang XJ, Seto E. The Rpd3/Hda1 family of lysine deacetylases: from bacteria and yeast to mice and men. Nat Rev Mol Cell Biol. 2008;9(3):206–18. doi:10.1038/nrm2346.
17. Grunstein M. Histone acetylation in chromatin structure and transcription. Nature. 1997;389(6649):349–52. doi:10.1038/38664.
18. Valente S, Mai A. Small-molecule inhibitors of histone deacetylase for the treatment of cancer and non-cancer diseases: a patent review (2011–2013). Expert Opin Ther Pat. 2014. doi:10.1517/13543776.2014.877446.
19. Ververis K, Hiong A, Karagiannis TC, Licciardi PV. Histone deacetylase inhibitors (HDACIs): multitargeted anticancer agents. Biol: Targets Ther. 2013;7:47–60. doi:10.2147/BTT.S29965.
20. Niegisch G, Knievel J, Koch A, Hader C, Fischer U, Albers P, et al. Changes in histone deacetylase (HDAC) expression patterns and activity of HDAC inhibitors in urothelial cancers. Urol Oncol. 2013;31(8):1770–9. doi:10.1016/j.urolonc.2012.06.015.
21. Vallo S, Xi W, Hudak L, Juengel E, Tsaur I, Wiesner C, et al. HDAC inhibition delays cell cycle progression of human bladder cancer cells in vitro. Anti-Cancer Drugs. 2011;22(10):1002–9. doi:10.1097/CAD.0b013e32834a2c70.
22. Oehme I, Deubzer HE, Wegener D, Pickert D, Linke JP, Hero B, et al. Histone deacetylase 8 in neuroblastoma tumorigenesis. Clin Cancer Res. 2009;15(1):91–9. doi:10.1158/1078-0432.CCR-08-0684.
23. Lehmann M, Hoffmann MJ, Koch A, Ulrich SM, Schulz WA, Niegisch G. Histone deacetylase 8 is deregulated in urothelial cancer but not a target for efficient treatment. J Exp Clin Cancer Res: CR. 2014;33:59. doi:10.1186/s13046-014-0059-8.
24. Pinkerneil M, Hoffmann MJ, Deenen R, Köhrer K, Arent T, Schulz WA, et al. Inhibition of class I histone deacetylases 1 and 2 promotes urothelial carcinoma cell death by various mechanisms. Mol Cancer Ther. 2016;15(2):299–312. doi:10.1158/1535-7163.MCT-15-0618.
25. Tresckow B, Gundermann S, Eichenauer DA, Aulitzky WE, Göbeler M, Sayehli C et al. First-in-human study of 4SC-202, a novel oral HDAC inhibitor in advanced hematologic malignancies (TOPAS study). Journal of Clinical Oncology. 2014;32(supplement 5):abstr. 8559.
26. Swiatkowski S, Seifert HH, Steinhoff C, Prior A, Thievessen I, Schliess F, et al. Activities of MAP-kinase pathways in normal uroepithelial cells and urothelial carcinoma cell lines. Exp Cell Res. 2003;282(1):48–57.
27. Cross WR, Eardley I, Leese HJ, Southgate J. A biomimetic tissue from cultured normal human urothelial cells: analysis of physiological function. Am J Physiol Renal Physiol. 2005;289(2):F459–68. doi:10.1152/ajprenal.00040.2005.
28. Nicoletti I, Migliorati G, Pagliacci MC, Grignani F, Riccardi C. A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. J Immunol Methods. 1991;139(2):271–9.
29. Shechter D, Dormann HL, Allis CD, Hake SB. Extraction, purification and analysis of histones. Nat Protoc. 2007;2(6):1445–57. doi:10.1038/nprot.2007.202.
30. Rosik L, Niegisch G, Fischer U, Jung M, Schulz WA, Hoffmann MJ. Limited efficacy of specific HDAC6 inhibition in urothelial cancer cells. Cancer Biol Ther. 2014;15(6):742–57.
31. Bonner WM, Redon CE, Dickey JS, Nakamura AJ, Sedelnikova OA, Solier S, et al. GammaH2AX and cancer. Nat Rev Cancer. 2008;8(12):957–67. doi:10.1038/nrc2523.
32. Rogakou EP, Pilch DR, Orr AH, Ivanova VS, Bonner WM. DNA double-stranded breaks induce histone H2AX phosphorylation on serine 139. J Biol Chem. 1998;273(10):5858–68.
33. Wei DG, Chiang V, Fyne E, Balakrishnan M, Barnes T, Graupe M, et al. Histone deacetylase inhibitor romidepsin induces HIV expression in CD4 T cells from patients on suppressive antiretroviral therapy at concentrations achieved by clinical dosing. PLoS Pathog. 2014;10(4), e1004071. doi:10.1371/journal.ppat.1004071.
34. Scholz C, Weinert BT, Wagner SA, Beli P, Miyake Y, Qi J, et al. Acetylation site specificities of lysine deacetylase inhibitors in human cells. Nat Biotechnol. 2015;33(4):415–23. doi:10.1038/nbt.3130.
35. Bantscheff M, Hopf C, Savitski MM, Dittmann A, Grandi P, Michon AM, et al. Chemoproteomics profiling of HDAC inhibitors reveals selective targeting of HDAC complexes. Nat Biotechnol. 2011;29(3):255–65. doi:10.1038/nbt.1759.
36. Halsall JA, Turan N, Wiersma M, Turner BM. Cells adapt to the epigenomic disruption caused by histone deacetylase inhibitors through a coordinated, chromatin-mediated transcriptional response. Epigenetics Chromatin. 2015;8:29. doi:10.1186/s13072-015-0021-9.
37. Lee JH, Choy ML, Ngo L, Foster SS, Marks PA. Histone deacetylase inhibitor induces DNA damage, which normal but not transformed cells can repair. Proc Natl Acad Sci U S A. 2010;107(33):14639–44. doi:10.1073/pnas.1008522107.
38. Henning SW, Doblhofer R, Kohlhof H, Jankowsky R, Maier T, Beckers T, et al. Preclinical characterization of 4SC-202, a novel isotype specific HDAC inhibitor. Eur J Cancer Suppl. 2010;8(7):61 (abstr. 178).
39. Fei DL, Sanchez-Mejias A, Wang Z, Flaveny C, Long J, Singh S, et al. Hedgehog signaling regulates bladder cancer growth and tumorigenicity. Cancer Res. 2012;72(17):4449–58. doi:10.1158/0008-5472.CAN-11-4123.
40. Majid S, Saini S, Dahiya R. Wnt signaling pathways in urological cancers: past decades and still growing. Mol Cancer. 2012;11:7. doi:10.1186/1476-4598-11-7.
41. Singh MM, Manton CA, Bhat KP, Tsai WW, Aldape K, Barton MC, et al. Inhibition of LSD1 sensitizes glioblastoma cells to histone deacetylase inhibitors. Neuro Oncol. 2011;13(8):894–903. doi:10.1093/neuonc/nor049.
42. Bose P, Dai Y, Grant S. Histone deacetylase inhibitor (HDACI) mechanisms of action: emerging insights. Pharmacol Ther. 2014;143(3):323–36. doi:10.1016/j.pharmthera.2014.04.004.
43. Frew AJ, Johnstone RW, Bolden JE. Enhancing the apoptotic and therapeutic effects of HDAC inhibitors. Cancer Lett. 2009;280(2):125–33. doi:10.1016/j.canlet.2009.02.042.
44. Falkenberg KJ, Johnstone RW. Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders. Nat Rev Drug Discov. 2014;13(9):673–91. doi:10.1038/nrd4360.
45. Lai F, Guo ST, Jin L, Jiang CC, Wang CY, Croft A, et al. Cotargeting histone deacetylases and oncogenic BRAF synergistically kills human melanoma cells by necrosis independently of RIPK1 and RIPK3. Cell Death Dis. 2013;4:e655. doi:10.1038/cddis.2013.192.
46. Florl AR, Schulz WA. Chromosomal instability in bladder cancer. Arch Toxicol. 2008;82(3):173–82. doi:10.1007/s00204-008-0280-3.
47. Zhijun H, Shusheng W, Han M, Jianping L, Li-Sen Q, Dechun L. Pre-clinical characterization of 4SC-202, a novel class I HDAC inhibitor, against colorectal cancer cells. Tumour Biol. 2016. doi:10.1007/s13277-016-4868-6.
48. Fu M, Wan F, Li Z, Zhang F. 4SC-202 activates ASK1-dependent mitochondrial apoptosis pathway to inhibit hepatocellular carcinoma cells. Biochem Biophys Res Commun. 2016;471(2):267–73. doi:10.1016/j.bbrc.2016.01.030.
49. Valls E, Sanchez-Molina S, Martinez-Balbas MA. Role of histone modifications in marking and activating genes through mitosis. J Biol Chem. 2005;280(52):42592–600. doi:10.1074/jbc.M507407200.
50. Chuang C, Lin SH, Huang F, Pan J, Josic D, Yu-Lee LY. Acetylation of RNA processing proteins and cell cycle proteins in mitosis. J Proteome Res. 2010;9(9):4554–64. doi:10.1021/pr100281h.
51. Kuffer C, Kuznetsova AY, Storchova Z. Abnormal mitosis triggers p53-dependent cell cycle arrest in human tetraploid cells. Chromosoma. 2013;122(4):305–18. doi:10.1007/s00412-013-0414-0.
52. Knowles MA, Hurst CD. Molecular biology of bladder cancer: new insights into pathogenesis and clinical diversity. Nat Rev Cancer. 2015;15(1):25–41. doi:10.1038/nrc3817.
53. Earl J, Rico D, Carrillo-de-Santa-Pau E, Rodriguez-Santiago B, Mendez-Pertuz M, Auer H, et al. The UBC-40 urothelial bladder cancer cell line index: a genomic resource for functional studies. BMC Genomics. 2015;16:403. doi:10.1186/s12864-015-1450-3.